研究乙酰-L-亮氨酸治疗三种超罕见神经退行性疾病的主方案
为应对罕见病药物开发挑战,研究者制定了一项主方案,在三个独立的II期试验中评估N-乙酰-L-亮氨酸对Niemann-Pick C型、GM2神经节苷脂沉积症和共济失调毛细血管扩张症的治疗作用。研究采用开放标签、评分者盲法设计,主要终点为临床严重程度变化印象(CI-CS),通过标准化视频由独立盲法评分者评估。该设计旨在提高超罕见人群试验的可行性,并捕捉对患者生活质量有意义的细微变化。
要点
- 主方案覆盖三种超罕见神经退行性疾病,采用开放标签、评分者盲法设计。
- 主要终点CI-CS基于患者个体化选择的锚定测试(8MWT或9HPT-D)的标准化视频。
- 治疗评估包括6周母研究和1年扩展期,以区分症状性和疾病修饰效应。
核心结论
- N-乙酰-L-亮氨酸在NPC、GM2和A-T三种超罕见病中的疗效尚待三项II期试验结果确定。
研究设计与样本
- 采用主方案设计,包含三个独立、多国、II期试验,分别针对NPC、GM2和A-T。
- 试验为开放标签、评分者盲法,评估N-乙酰-L-亮氨酸(IB1001)的疗效和安全性。
- 治疗序列包括6周母研究和1年扩展期。
主要发现
- 原文未报告试验结果,仅描述方案设计和终点评估方法。
关键数值与推荐
- 主要终点为CI-CS,由独立盲法评分者基于标准化视频采用7点Likert量表评估。
- 锚定测试为8米步行测试(8MWT)或优势手9孔钉板测试(9HPT-D),由主要研究者根据患者症状选择。
- 视频采集包括基线、治疗结束和洗脱后三个时间点。
临床怎么用
- CI-CS评估可捕捉对患者生活质量重要的细微功能变化(精细运动技能、步态)。
- 主方案设计可能为其他孤儿病治疗开发提供新范式。
局限性
- 开放标签设计可能引入偏倚,但主要终点采用盲法评估以降低风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for these rare populations and thereby expedite the approval of promising treatments to address patients' high unmet medical need. Here, we describe the development of an innovative master protocol and primary outcome assessment to investigate the modified amino acid N-acetyl-L-leucine (Sponsor Code: IB1001) in three separate, multinational, phase II trials for three ultra-rare, autosomal-recessive, neurodegenerative disorders: Niemann-Pick disease type C (NPC), GM2 gangliosidoses (Tay-Sachs and Sandhoff disease; "GM2"), and ataxia telangiectasia (A-T). METHODS/DESIGN: The innovative IB1001 master protocol and novel CI-CS primary endpoints were developed through a close collaboration between the Industry Sponsor, Key Opinion Leaders, representatives of the Patient Communities, and National Regulatory Authorities. As a result, the open-label, rater-blinded study design is considerate of the practical limitations of recruitment and retention of subjects in these ultra-orphan populations. The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the principal investigator appoints for each patient a primary anchor test (either the 8-m walk test (8MWT) or 9-hole peg test of the dominant hand (9HPT-D)) based on his/her unique clinical symptoms. The anchor tests are videoed in a standardized manner at each visit to capture all aspects related to the patient's functional performance. The CI-CS assessment is ultimately performed by independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end of treatment, and the end of a post-treatment washout. Blinded to the time point of each video, the raters make an objective comparison scored on a 7-point Likert scale of the change in the severity of the patient's neurological signs and symptoms from video A to video B. To investigate both the symptomatic and disease-modifying effects of treatment, N-acetyl-L-leucine is assessed during two treatment sequences: a 6-week parent study and 1-year extension phase. DISCUSSION: The novel CI-CS assessment, developed through a collaboration of all stakeholders, is advantageous in that it better ensures the primary endpoint is functionally relevant for each patient, is able to capture small but meaningful clinical changes critical to the patients' quality of life (fine-motor skills; gait), and blinds the primary outcome assessment. The results of these three trials will inform whether N-acetyl-L-leucine is an effective treatment for NPC, GM2, and A-T and can also serve as a new therapeutic paradigm for the development of future treatments for other orphan diseases. TRIAL REGISTRATION: The three trials (IB1001-201 for Niemann-Pick disease type C (NPC), IB1001-202 for GM2 gangliosidoses (Tay-Sachs and Sandhoff), IB1001-203 for ataxia telangiectasia (A-T)) have been registered at www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678), www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39), and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511).
引用
- Fields T, Patterson M, Bremova-Ertl T, et al. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials. 2021. PMID: 33482890. doi:10.1186/s13063-020-05009-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。